Streetbeat News

Products Services

DKNG

PARA

WBD

Former President Barack Obama has shared his NCAA Men's Basketball Tournament bracket for 2024, predicting Connecticut to win. His Final Four selections and their betting odds were provided by DraftKings. The 2024 tournament will be broadcast by Warner Bros. Discovery and Paramount Global across various platforms. Obama's tradition of sharing his bracket began in 2009, and he enjoys the competition it brings.

Portfolio Pulse from Chris Katje

March 20, 2024 | 9:27 pm

GOLD

Barrick Gold (NYSE:GOLD) is expanding its operations in the Democratic Republic of Congo and focusing on renewable energy initiatives, including a 16MW solar plant set for 2024. The company highlighted the success of its Kibali mine, emphasizing local economic development and responsible mining practices. Barrick is also planning to increase its presence in the African copper belt and has established the Barrick Academy in Tanzania to train over 2,000 personnel, supporting its growth and sustainability goals.

Portfolio Pulse from Stjepan Kalinic

March 20, 2024 | 9:08 pm

SMG

Scotts Miracle-Gro's subsidiary, Hawthorne Gardening, has entered into a strategic distribution partnership with BFG Supply. Under this partnership, BFG will distribute Hawthorne's proprietary Signature brand cultivation supplies and solutions.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 9:06 pm

ATI

CMC

COPX

NUE

Nucor Corporation has partnered with Mercedes-Benz to supply low-carbon steel for vehicle production, aligning with sustainability goals. ATI Inc. launched a new forging press to enhance titanium production for aerospace and defense. The Global X Copper Miners ETF saw a significant surge due to a rise in copper prices, driven by market tightness. Commercial Metals Company announced an increased quarterly dividend.

Portfolio Pulse from Austin DeNoce

March 20, 2024 | 9:06 pm

LLY

NVO

Eli Lilly's weight loss drugs, particularly Zepbound, have shown significant success, overtaking Novo Nordisk's Wegovy in US prescriptions. Despite this, Eli Lilly's fastest-growing treatment in sales was its cancer drug Verzenio. The weight-loss drug market is expected to grow substantially, with Eli Lilly and Novo Nordisk currently dominating. Eli Lilly's stock has seen remarkable gains, reflecting its market success and the potential of its product portfolio.

Portfolio Pulse from Neil Dennis

March 20, 2024 | 9:00 pm

VOR

Vor Biopharma anticipates releasing additional data on engraftment and protection from its VBP101 clinical trial in the second half of 2024. This update is crucial for investors monitoring the progress of Vor Biopharma's key clinical developments.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:34 pm

PG

Deep-pocketed investors have shown a bearish trend towards Procter & Gamble (NYSE:PG), with options activity indicating a divided sentiment but leaning more towards bearish with 66% against 33% bullish. Notable options activity includes both puts and calls with a target price range from $155.0 to $175.0. Procter & Gamble, a leading consumer product manufacturer, has seen its stock price slightly increase by 0.1%, reaching $161.99. Market experts have mixed opinions, with a consensus target price of $171.5.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 8:31 pm

NCNA

NuCana anticipates announcing data from the Phase 2 part of its Phase 1/2 study of NUC-7738 in combination with Pembrolizumab for melanoma treatment in FY24.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:27 pm

GTLS

Chart Industries, Inc. (GTLS) has announced a collaboration with GasLog LNG Services to focus on the deployment of large-scale liquid hydrogen. This partnership aims to leverage Chart Industries' expertise in liquid hydrogen technology and GasLog's experience in LNG services to advance the development and commercialization of liquid hydrogen as a clean energy source.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:26 pm

MU

Micron Technology Inc (NASDAQ:MU) reported fiscal Q2 earnings with revenue of $5.82 billion and adjusted EPS of 42 cents, surpassing analyst estimates. The company has beaten estimates for four consecutive quarters and expects Q3 revenue of $6.6 billion. Micron's strong performance and positive outlook, particularly in AI, drove its shares up 11.7% after hours.

Portfolio Pulse from Adam Eckert

March 20, 2024 | 8:19 pm